Nanoform Finland Oyj (NANOFH.HE)
EUR 1.29
(2.7%)
EUR 1.29
(2.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -17.65 Million EUR | -3.79% |
| 2022 | -19.25 Million EUR | -16.59% |
| 2021 | -16.94 Million EUR | 10.92% |
| 2020 | -17.93 Million EUR | -160.82% |
| 2019 | -6.93 Million EUR | -279.73% |
| 2018 | -1.82 Million EUR | -337.5% |
| 2017 | -419.35 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -5.32 Million EUR | 0.46% |
| 2024 Q2 | -5.72 Million EUR | 17.58% |
| 2023 Q3 | -2.99 Million EUR | 34.55% |
| 2023 Q1 | -2.16 Million EUR | 62.85% |
| 2023 Q4 | -5.35 Million EUR | -78.87% |
| 2023 FY | - EUR | -3.79% |
| 2023 Q2 | -4.57 Million EUR | -111.71% |
| 2022 Q3 | -4.08 Million EUR | 21.84% |
| 2022 FY | - EUR | -16.59% |
| 2022 Q4 | -5.81 Million EUR | -42.49% |
| 2022 Q2 | -5.22 Million EUR | -20.19% |
| 2022 Q1 | -4.34 Million EUR | 33.01% |
| 2021 Q1 | -2.78 Million EUR | 35.17% |
| 2021 Q3 | -3.85 Million EUR | 5.14% |
| 2021 Q4 | -6.48 Million EUR | -68.18% |
| 2021 Q2 | -4.06 Million EUR | -45.72% |
| 2021 FY | - EUR | 10.92% |
| 2020 FY | - EUR | -160.82% |
| 2020 Q4 | -4.3 Million EUR | -26.5% |
| 2020 Q3 | -3.4 Million EUR | 44.67% |
| 2020 Q2 | -6.14 Million EUR | -48.59% |
| 2020 Q1 | -4.13 Million EUR | -63.89% |
| 2019 Q1 | -1 Million EUR | 0.0% |
| 2019 Q4 | -2.52 Million EUR | -29.05% |
| 2019 FY | - EUR | -279.73% |
| 2019 Q3 | -1.95 Million EUR | -31.45% |
| 2019 Q2 | -1.48 Million EUR | -48.8% |
| 2018 FY | - EUR | -337.5% |
| 2017 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Biohit Oyj | 2.68 Million EUR | 756.449% |
| Herantis Pharma Oyj | 831.43 Thousand EUR | 2223.061% |